PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression.

Autor: Sun Y; Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology Suzhou Vocational Health College, Suzhou 215009, China., Yang J; Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology Suzhou Vocational Health College, Suzhou 215009, China., Chen Y; Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology Suzhou Vocational Health College, Suzhou 215009, China., Guo Y; Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology Suzhou Vocational Health College, Suzhou 215009, China., Xiong J; Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology Suzhou Vocational Health College, Suzhou 215009, China., Guo X; Center for Drug Metabolism and Pharmacokinetics College of Pharmaceutical Sciences Soochow University, Suzhou 215123, China., Zhang Y; Center for Drug Metabolism and Pharmacokinetics College of Pharmaceutical Sciences Soochow University, Suzhou 215123, China., Gu L; Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology Suzhou Vocational Health College, Suzhou 215009, China., Tong M; Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology Suzhou Vocational Health College, Suzhou 215009, China., Wang W; Center for Drug Metabolism and Pharmacokinetics College of Pharmaceutical Sciences Soochow University, Suzhou 215123, China., Sun J; Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology Suzhou Vocational Health College, Suzhou 215009, China.
Jazyk: angličtina
Zdroj: Journal of immunology research [J Immunol Res] 2024 Jul 02; Vol. 2024, pp. 3145695. Date of Electronic Publication: 2024 Jul 02 (Print Publication: 2024).
DOI: 10.1155/2024/3145695
Abstrakt: Background: This work focused on investigating the role of programmed death ligand 2 (PD-L2) in the progression of breast cancer by utilizing breast cancer specimens and cells.
Materials and Methods: The serum levels of soluble PD-L2 (sPD-L2) in breast cancer patients and healthy individuals were analyzed by means of the enzyme-linked immunosorbent assay, and the PD-L2 levels within 416 resected breast cancer specimens were assessed through immunohistochemistry. Concurrently, in vitro cell experiments and in vivo animal experiments were carried out to analyze the relationship between PD-L2 and the invasion and migration of breast cancer.
Results: The concentration of sPD-L2 in breast cancer patients significantly increased compared to that in the control groups. Additionally, breast cancer patients with high concentrations of sPD-L2 had higher Ki67 values (≥30%) and tumor grades. PD-L2 was expressed in 79.09% of the cancer samples, which exhibited a positive correlation with the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). Furthermore, we discovered that knockdown of PD-L2 inhibited the migratory and invasive abilities of both MCF-7 and MDA-MB231 cells.
Conclusion: Our findings demonstrated that knockdown of PD-L2 suppressed tumor growth, providing novel insights into important biological functions.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2024 Yuling Sun et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje